Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Apellis Pharmaceuticals (APLS) has announced it will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET. Interested participants must pre-register to access the live call.
The company will provide a live audio webcast with accompanying slides through the 'Events and Presentations' page on their website's 'Investors and Media' section. The webcast replay will be available for 90 days after the event.
Apellis Pharmaceuticals (APLS) ha annunciato che terrà una conferenza telefonica e un webcast per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024 venerdì 28 febbraio 2025, alle 8:30 ET. I partecipanti interessati devono registrarsi in anticipo per accedere alla chiamata dal vivo.
La società fornirà un webcast audio dal vivo con diapositive correlate tramite la pagina 'Eventi e Presentazioni' nella sezione 'Investitori e Media' del loro sito web. La registrazione del webcast sarà disponibile per 90 giorni dopo l'evento.
Apellis Pharmaceuticals (APLS) ha anunciado que llevará a cabo una conferencia telefónica y un webcast para discutir sus resultados financieros del cuarto trimestre y del año completo 2024 el viernes 28 de febrero de 2025, a las 8:30 a.m. ET. Los participantes interesados deben registrarse previamente para acceder a la llamada en vivo.
La empresa proporcionará un webcast de audio en vivo con diapositivas acompañantes a través de la página 'Eventos y Presentaciones' en la sección 'Inversores y Medios' de su sitio web. La repetición del webcast estará disponible durante 90 días después del evento.
Apellis Pharmaceuticals (APLS)는 2024년 4분기 및 연간 재무 결과를 논의하기 위해 2025년 2월 28일 금요일 오전 8시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 개최한다고 발표했습니다. 관심 있는 참가자는 라이브 통화에 접근하기 위해 사전 등록해야 합니다.
회사는 웹사이트의 '투자자 및 미디어' 섹션에 있는 '이벤트 및 발표' 페이지를 통해 관련 슬라이드와 함께 라이브 오디오 웹캐스트를 제공합니다. 웹캐스트 재생은 이벤트 후 90일 동안 이용 가능합니다.
Apellis Pharmaceuticals (APLS) a annoncé qu'elle organisera une conférence téléphonique et un webinaire pour discuter de ses résultats financiers du quatrième trimestre et de l'année complète 2024 le vendredi 28 février 2025, à 8h30 ET. Les participants intéressés doivent s'inscrire à l'avance pour accéder à l'appel en direct.
L'entreprise proposera un webinaire audio en direct avec des diapositives d'accompagnement via la page 'Événements et Présentations' dans la section 'Investisseurs et Médias' de son site web. La rediffusion du webinaire sera disponible pendant 90 jours après l'événement.
Apellis Pharmaceuticals (APLS) hat angekündigt, dass es am Freitag, den 28. Februar 2025, um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten wird, um die Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 zu besprechen. Interessierte Teilnehmer müssen sich im Voraus registrieren, um auf den Live-Anruf zugreifen zu können.
Das Unternehmen wird einen Live-Audio-Webcast mit begleitenden Folien über die Seite 'Veranstaltungen und Präsentationen' im Bereich 'Investoren und Medien' seiner Website bereitstellen. Die Wiederholung des Webcasts wird 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET.
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
When will Apellis Pharmaceuticals (APLS) report Q4 and full year 2024 earnings?
How can investors access Apellis Pharmaceuticals' (APLS) Q4 2024 earnings call?
How long will Apellis Pharmaceuticals' (APLS) Q4 2024 earnings webcast be available?
What does Apellis Pharmaceuticals (APLS) specialize in?
